Kornimate/medical-research-clean huggingface dataset:
hormone replacement therapy and prothrombotic variants

Conditions: Cardiovascular Diseases; Heart Diseases; Cerebrovascular Accident; Myocardial Infarction; Hypertension

Summary: to examine in postmenopausal women the potential interactions of hormone replacement therapy with other blood clotting factors on the risk of cardiovascular diseases such as heart attack or stroke.

background: estrogens are prothrombotic. recently, the heart and estrogen/progestin replacement study (hers), renewed interest in the adverse effects of hormone replacement therapy (hrt). in hers, hrt was no better than placebo at preventing coronary events. in post hoc analyses, treatment was associated with early harm and late benefit. in an american heart association funded case-control study, a potential interaction was observed between hrt and the prothrombin g20210a variant on the risk of first myocardial infarction (mi) in post-menopausal women with hypertension. design narrative: the study has a case-control design. the group health cooperative (ghc) computerized files will be used to identify postmenopausal women, aged 30 to 79 yrs, with incident myocardial infarction (mi) or stroke during 1/2000-12/2004. population-based controls, sampled from the ghc enrollment files, will be frequency matched to cases by age, calendar year, and treated hypertension. data collection will include medical-record review, telephone interview of consenting subjects, and venous-blood collection. standard methods will be used to assay variant alleles. the ghc computerized pharmacy records will serve as the primary source of information about the use of hrt. data analysis will involve restriction, stratification, and logistic regression. case-control and case-only analyses are planned. there will be a total of 600 mi cases, 420 stroke cases and 1800 controls. the primary purpose is to examine the potential interactions of hormone replacement therapy with other procoagulant variants on the risk of cardiovascular events. the main variants of interest are: (la) factor xiiia val34leu; (ib) platelet glycoprotein (pgp) jib ile843ser; (ic) pgp iiia leu33pro; and (id) pgp ia c807t. the secondary aims include the assessment of other drug-gene, risk-factor-gene or gene-gene interactions on risk: (2a) the interaction between pgp iib ser843, pgp lila leu33pro and pgp ia c807t and traditional cardiovascular risk factors such as smoking and obesity on the risk of mi and stroke; (2b) the interaction between three coagulation factor xiii polymorphisms and pal-1 4g/5g on the risk of stroke in women; and (2c) the interaction between aspirin use and glycoprotein iiia leu33pro on the risk of mi and stroke.

Eligibility criteria:
no eligibility criteria
special investigation (long-term investigation) in patients with crohn's disease

Conditions: Crohn's Disease

Summary: this study of humira will be conducted to obtain information on the safety (especially profile of malignant tumors and serious infections) and effectiveness in patients with crohn's disease who are receiving humira for a long period of time.


Eligibility criteria:
inclusion criteria: * patients with crohn's disease indicated for humira treatment with the recommended dosage regimen * patients with no past- or present malignant tumors * patients who are not currently receiving humira exclusion criteria: * none.

Keywords: crohn's disease
comparison of 5-ala photodynamic therapy and co2 laser for treating persistent low-grade cervical lesions with high-risk hpv infection

Conditions: HPV-Related Cervical Carcinoma; Low-Grade Squamous Intraepithelial Lesions; HPV Infection; Photodynamic Therapy

Summary: non-rct clinical trial comparing 5-ala photodynamic therapy and co2 laser for persistent high-risk hpv-related low-grade cervical lesions.

this non-randomized controlled trial aims to compare the effectiveness of two treatments, 5-aminolevulinic acid (5-ala) photodynamic therapy and co2 laser, for women with persistent low-grade cervical lesions associated with high-risk hpv infection lasting more than one year. the study's primary objective is to assess which treatment option yields better results. participants in both groups will undergo specific therapeutic procedures, including 5-ala photodynamic therapy or co2 laser treatment. the study will analyze and compare the effects of these therapies on the regression or elimination of cervical lesions, offering valuable insights into the management of persistent low-grade cervical lesions among high-risk hpv-infected women.

Eligibility criteria:
inclusion criteria: 1. aged 18-65 years old with a history of sexual activity. 2. subclinical infected individuals who have been confirmed as hr-hpv positive (if there is the same positive type in the typing test) for more than 1 year using hpv typing test, hpv e6/e7 mrna test, hpv dna test, and cervical triple step diagnostic procedure (cytology colposcopy histopathology). 3. patients diagnosed with lsil by pathological examination of cervical biopsy under colposcopy with an interval of more than 1 year. 4. no fundamental diseases of important organs. 5. agree to receive treatment and/or follow-up according to regulations and sign an informed consent form. 6. there has been no history of using other drugs related to hpv infection in the past 3 months. exclusion criteria: 1. hr-hpv persistent infection. 2. a total hysterectomy has been performed. 3. concomitant endometrial cancer, ovarian cancer, and other reproductive tract tumors. 4. complicated with abnormal heart, liver, and kidney functions, immune dysfunction, or immune system diseases such as systemic lupus erythematosus (sle). 5. using drugs such as immunosuppressants, antiviral agents, and glucocorticoids. 6. pregnant and lactating women. 7. acute reproductive tract inflammation. 8. diabetes patients with uncontrolled blood sugar. 9. patients who do not receive full treatment and follow-up. 10. those who fail to sign the informed consent form.

Keywords: high-risk hpv infection hpv persistent lsil cervical lesions
a safety and efficacy study with ym543 in type 2 diabetes mellitus subjects

Conditions: Diabetes Mellitus Type 2

Summary: the purpose of this study is to investigate the safety of ym543 in type 2 diabetes mellitus patients and to investigate whether this study drug is effective in these patients


Eligibility criteria:
inclusion criteria: * treatment-naive subjects diagnosed with t2dm * stable diet and exercise program for at least 6 weeks * inadequate glycemic control indicated by hba1c and fpg level at visit 1 exclusion criteria: * any known complication of t2dm indicating a late disease state, clinical manifestations of macro- and/or micro vascular disorders * use of insulin or oral blood glucose lowering drugs in the last 3 months

Keywords: diabetes mellitus type 2 ym543 treatment safety efficacy
celiac plexus block to reduce opioid consumption following hepato-pancreato-biliary mini-invasive surgery

Conditions: Pancreatic Ductal Adenocarcinoma; Liver, Cancer of, Primary Resectable

Summary: the goal of this study is to assess the efficacy of intraoperative celiac plexus block (cpb) to reduce opioid consumption following laparoscopic hepato-pancreato-biliary surgery

a bilateral cpb is convenient and safe to perform under the direct laparoscopic vision of the surgeons during surgery; however, perspective data are warranted. the investigators hypothesize that a bilateral cpb using 0.5% ropivacaine will improve the quality of recovery following a laparoscopic hepato-pancreato-biliary surgery. the primary endpoint is the postoperative opioid use. secondary endpoints include acute postoperative pain, opioid consumption, the incidence of postoperative nausea or vomiting (ponv), the 15-item quality of recovery questionnaire (qor-15), length of post-anesthesia care unit (pacu) stay, length of post-operative hospital stay, and chronic post-surgical pain at 90 d after surgery.

Eligibility criteria:
inclusion criteria: * over age 18 * undergoing laparoscopic hepato-pancreato-biliary surgery exclusion criteria: * patient refuse * relatively contraindications: severe heart, liver, or kidney dysfunction, coagulation dysfunction, and local anesthetic allergy history * intervention unlikely to be effective: drug abuse history, receiving other types of nerve block treatment * unlikely to complete the follow-up: alcoholism, planned to replace wechat and phone within three months; the expected life span less than three months * unable to cooperate with the questionnaire and use the patient-controlled analgesia pump

Keywords: laparoscopic hepato-pancreato-biliary surgery
comparison between winged versus traditional plastic stents for biliary drainage

Conditions: Biliary Obstruction; Bile Duct Stones; Biliary Tract Cancer

Summary: this study was randomized, controlled, blinded trial with a two-arm parallel-group design to directly compare the therapeutic outcomes of winged versus conventional stents in patients with benign or malignant biliopancreatic conditions requiring ercp and subsequent insertion or replacement of plastic stents.

procedure the study was structured as a randomized, controlled trial using a two-arm parallel group design to compare different therapies (winged stent vs. conventional stent). randomization was carried out in a 1:1 ratio using block randomization. upon stent exchange, participants were switched to the alternate treatment group. each subject was intended to receive both forms of therapy over the course of the treatment periods in a crossover design, with only the sequence of therapies being determined randomly (figure 1). the procedures were conducted using standard techniques. no additional steps, biopsies, or similar procedures were required. for the ercps carried out in the endoscopy department of the university hospital leipzig, fujifilm video duodenoscopes were utilized data on the procedure date, we gathered essential baseline and procedural information including demographic data (age and gender), previous stent interventions, diagnostic imaging and laboratory results, specifics of the stent used (type, diameter, and length), the effectiveness of the stent insertion, and any associated complications. beyond standard care, follow-up was conducted at intervals of one week, one month, and two months post-intervention, utilizing a methodical questionnaire to monitor clinical progress and evaluate for any stent-related dysfunction."

Eligibility criteria:
inclusion criteria: * biliopancreatic disorder requiring plaxtic biliary stent therapy * written informed consent exclusion criteria: * pregnancy * breastfeeding * live expectancy of less than one month * biliary drainage by metal stent or external drainage.

Keywords: ercp biliary obstruction biliary stenting plastic stent
insulin dosing in diabetic patients with end stage renal disease (esrd) or hemodialysis

Conditions: Diabetes; Hypoglycemia; Renal Dysfunction; Insulin Dosing

Summary: the purpose of this study is to assess whether the current recommendation for a 50% dose reduction in insulin for diabetic patients with a creatinine clearance (crcl) ≤15 ml/min or on hemodialysis results in an increased number of hypoglycemic episodes.


Eligibility criteria:
inclusion criteria: * inpatient men and women 18 years of age and older with a diagnosis of type 2 diabetes mellitus (t2dm) with crcl ≥60, 16-59 or ≤15 milliliters/minute. exclusion criteria: * patients less than 18 years of age, pregnant patients

Keywords: diabetes renal failure dialysis end stage renal disease hypoglycemia
efficacy of botulinum toxin and marjoram oil applications in bruxism

Conditions: Bruxism, Sleep

Summary: objective: bruxism is defined as clenching or grinding teeth unconsciously. it can be categorized under two subheadings: sleep and awake bruxism. this study aims to investigate the effectiveness of botox applications, a current approach in the treatment of sleep bruxism, and to evaluate the effectiveness of alternative therapies like aromatherapeutic oils. the study will compare and assess the efficacy of these methods. materials and methods: this prospective study will be conducted between march 2024 and january 2025 at bezmialem vakıf university, faculty of dentistry, department of oral and maxillofacial radiology, with patients aged between 18 and 60 who have presented complaints of clenching/grinding teeth, sleep bruxism, jaw, neck, or face pain, and insomnia. the patients diagnosed with sleep bruxism will be divided into two groups, each consisting of 15 patients. the first group will include 15 patients with sleep bruxism who will receive botulinum toxin-a (btx-a) injections, and the second group will consist of 15 patients who will use marjoram oil as an alternative treatment. fractal analysis of the condyle and corpus regions will be conducted on panoramic radiographs before treatment and 3 months after treatment. ultrasound imaging will assess the thickness and stiffness of the masseter muscle before treatment, and at 1 and 3 months post-treatment. clinical evaluations will also be performed before treatment, and at 1 and 3 months post-treatment using scoring systems.


Eligibility criteria:
inclusion criteria: 1. patients who have complaints of teeth clenching or grinding, 2. patients who present with tired or tense jaw muscles or a locked jaw that cannot fully open or close, 3. patients who experience jaw, neck, or facial pain due to teeth grinding, 4. patients who feel ear pain that mimics an ear problem despite having no ear issues, 5. patients with abnormal tooth wear, sounds associated with bruxism, and discomfort in the jaw muscles, 6. patients who have sleep problems due to jaw, neck, or facial pain complaints, 7. individuals older than 18 years, 8. individuals younger than 60 years, 9. patients who are willing to participate in the study. exclusion criteria: 1. patients who have had masseter botox within the last 6 months, 2. patients who have used a night guard for bruxism in the last 6 months, 3. patients with a history of alcohol or substance abuse, 4. patients under the age of 18, 5. patients over the age of 60, 6. pregnant women or those suspected of being pregnant, 7. postpartum and breastfeeding women, 8. patients with infections or skin diseases at the injection site, 9. patients diagnosed with asthma or copd, 10. patients allergic to or who have skin reactions to btx-a and/or aromatherapy oils.

Keywords: bruxism botox origanum majorana ultrasonography
effects of smoking on bronchial epithelium

Conditions: Asthma; Copd

Summary: asthma and chronic obstructive pulmonary disease (copd) are chronic inflammatory airway diseases affecting millions of people worldwide. inhaled corticosteroids (ics) are by far the most effective treatment with a broad anti-inflammatory spectrum. nevertheless, most copd patients and a proportion of severe asthma patients are corticosteroid-resistant (cr) and to fail to respond to ics even when higher doses are given. these corticosteroid-resistant patients suffer from persistent symptoms and repeated asthma exacerbations. it has been suggested that smoking and oxidative stress may induce corticosteroid-resistance. the reactive oxygen species (ros) responsible for oxidative stress can be generated exogenously (air pollutants, cigarette smoke) and endogenously by metabolic reactions. after inhaling air pollutants or cigarette smoke, the bronchial epithelium is exposed. preliminary data from our own lab suggest that smoking and oxidative stress may decrease epithelial cell-cell contact formation. this results not only in a decreased barrier function, but also in an increased production of pro-inflammatory mediators.


Eligibility criteria:
inclusion criteria: inclusion criteria for patients with allergic asthma: * age between 18 and 65 years. * \< 10 packyears, no smoking in the last year. * the presence of allergy defined as at least one positive wheal/flare reaction (2 mm relative to control) to a skin prick test with sixteen common aero-allergens). * fev1 \> 80% predicted. * pc20 methacholine or pc20 histamine \< 8 mg/ml. inclusion criteria for patients with copd: * age between 45-75 years. * ≥ 10 packyears. * fev1 between 30% and 80% of predicted. exclusion criteria: * any disease that, as judged by the investigator, could have affected the outcome of this study. * a respiratory tract infection within 4 weeks of the start of the study. * a history of life-threatening asthma, defined as exacerbation of asthma or copd that required intubation or was associated with hypercapnea. * history of myocardial infarction or documented myocardial ischemia. * pregnancy, or the possibility of being pregnant (a pregnancy test will be performed in women of childbearing potential who do not use adequate anticonception as judged by the investigator).

Keywords: inflammation epithelial integrity ecis
primary tumor radiotherapy omitting ctv for patients with advanced nsclc responded to immunotherapy and chemotherapy

Conditions: Advanced Non-Small Cell Squamous Lung Cancer; Radiotherapy; Immunotherapy

Summary: the aim of this randomized study is to investigate pneumonitis, local tumor control, and survival outcomes of primary tumor radiotherapy omitting ctv for patients with advanced nsclc responded to immunotherapy and chemotherapy

studies have confirmed that systemic therapy combined with primary tumor radiotherapy can improve symptoms and prolong survival of advanced nsclc. our previous sturdy indicated that patients who received immunotherapy and subsequent radiotherapy suffered higher proportion of pneumonitis. patients suffered grade 2 or more pneumonitis have worse prognosis. it is urged to optimize the radiotherapy dose and target volume for patients treated with immunotherapy and radiotherapy. according to retrospective and prospective studies, omitting primary tumor ctv radiation therapy showed no reduction in local control and survival for locally advanced nsclc. it is postulated that omitting ctv radiation for patients responded to therapy with immunotherapy and chemotherapy will have less pneumonitis without sacrificing the local control rate. omitting ctv may also retain better immune function which will facilitate the immunotherapy.

Eligibility criteria:
inclusion criteria: 1. histologically or cytologically confirmed advanced non-small cell lung cancer (according to the 8th edition of the tnm cancer staging system of ajcc and uicc); 2. after over two cycles of chemotherapy combined with immunotherapy, the efficacy was cr, pr or sd (with a decreasing trend); 3. age 18 to 80 years old, performance status 0-1; 4. measurable or evaluable lesions; 5. survival expectancy is not less than 6 months; 6. adequate cardiac, pulmonary, renal, and hepatic and bone marrow function exclusion criteria: 1. tumor progress after therapy with immunotherapy and chemotherapy 2. egfr, alk, or ros1 mutation; 3. previous thoracic radiotherapy; 4. grade 2 or more immune-related adverse events after induction immunotherapy 5. previous malignancies (except stage i non-melanic skin cancer or cervical carcinoma in situ); 6. pregnant or lactating women 7. undergoing other clinical trials; 8. have serious comorbidities, including myocardial infarction, severe arrhythmia, severe cerebrovascular disease, ulcer disease, psychosis and uncontrollable diabetes; 9. patients with hiv positive and undergoing antiviral therapy; 10. active tuberculosis

Keywords: omitting ctv
serum and peritoneal fluid bank for endometriosis markers

Conditions: Endometriosis

Summary: the purpose of this study is to investigate differences in protein expression profiles of blood and peritoneal fluid samples obtained from patients who do, and those who do not, have endometriosis seen during laparoscopic surgery. these profiles may include both known and novel markers for diagnosing endometriosis.


Eligibility criteria:
inclusion criteria: * undergoing laparoscopic surgery for one of the following indications: 1. infertility 2. pain 3. tubal sterilization * for cases, visualization of endometriosis * for controls, absence of endometriosis exclusion criteria: * none

Keywords: endometriosis
oxytocin and sleeve gastrectomy

Conditions: Obesity, Morbid

Summary: morbid obesity has become a common condition and there is no effective drug that is able to induce a sustained weight loss. currently bariatric surgery remains the only effective means that is able to lead to long term sustained weight loss. oxytocin is a hormone secreted by the hypophysis that regulates negatively the adipogenesis and positively the osteogenesis. oxytocin also regulates appetite and its role in weight loss in humans has not been investigated so far. the aim of the present study is to elucidate whether plasma levels of oxytocin and sleeve gastrectomy induced weight loss are correlated in pre-menopausal morbidly obese women.


Eligibility criteria:
inclusion criteria: * women aged 18-65, pre-menopausal, * able to read and understand the written informed consent, * with a bmi \> 40 or 35 * with at least one obesity linked comorbidity among blood hypertension, * type 2 diabetes, * sleep apnea syndrome, * invalidating arthritis, * indication for sleeve gastrectomy * accepted by the multidisciplinary committee and the cpam (local health care system agency), * affiliation to the fre,nch health care system, * signature of the informed consent. exclusion criteria: * post-menopausal women, * any other bariatric procedure that sleeve gastrectomy, history of any other bariatric procedure, * pregnancy, * age less than 18 years under, under guardianship * patients undergoing any other procedure that the planned sleeve gastrectomy or undergoing a second bariatric procedure for a complications during the 6 months follow-up.
internet-delivered cognitive behavior therapy for anxiety and depression amongst french canadians

Conditions: Major Depression; Anxiety Disorders

Summary: this study represents phase ii of a research program involving an international collaboration with macquarie university (sydney, australia) to implement an internet-based cognitive behavior therapy for the treatment of anxiety and depression in french-speaking canadians from the atlantic provinces. the primary objective is to establish the clinical efficacy of a french-canadian self-guided format version of the wellbeing course by conducting a randomized-control trial where an experimental group will be compared to a waitlist control group. a secondary objective is to demonstrate the course's acceptability through participants' satisfaction with the course.


Eligibility criteria:
inclusion criteria: * residing in new-brunswick, nova-scotia, prince edward island, or newfound land \& labrador * having identified french as the first official language spoken and having good reading comprehension in french. * reliable internet access * clinically significant levels of depression or anxiety reflected by significant scores on the following measures: phq-9 \> 9, gad-7 \>7, penn stage worry questionnaire ≥ 45, social phobia inventory ≥ 19, panic and agoraphobia scale ≥ 19, or by answering yes to the question "is anxiety or low mood a problem for you" * not currently participating in cognitive-behavioral therapy * no changes in medication for 4 weeks prior to the study, nor any changes in medication for the next 2 months * willing to disclose personal information exclusion criteria: * presence of psychotic symptoms * presence of severe depression as indicated by scores ≥ 23 on the phq-9, or a score \> 2 on item 9 of the phq-9